Cited 19 times in
Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2014-12-18T08:35:11Z | - |
dc.date.available | 2014-12-18T08:35:11Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0090-4295 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86583 | - |
dc.description.abstract | OBJECTIVE: To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program. METHODS: Patients with metastatic renal cell carcinoma refractory to vascular endothelial growth factor receptor-tyrosine kinase inhibitor received everolimus (10 mg once daily), with dosing interruption or modifications allowed for toxicity. All serious and grade 3/4 adverse events and grade 1/2 adverse events leading to a change in drug administration were reported. Tumor response was evaluated using Response Evaluation Criteria In Solid Tumors. RESULTS: The study stratified 1367 evaluable patients into treatment duration groups of <3 months, ≥3 and <6 months, ≥6 months and <1 year, and ≥1 year. Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for ≥1 year but did not result in treatment discontinuations. First occurrence of adverse events presented early in the treatment course for most patients. Treatment duration of ≥6 months was associated with improved disease control rates. CONCLUSION: Everolimus is well tolerated in patients with metastatic renal cell carcinoma for treatment durations≥1 year and not associated with cumulative toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anemia/chemically induced | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects* | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/secondary | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Dyspnea/chemically induced | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Fatigue/chemically induced | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyperglycemia/chemically induced | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pneumonia/chemically induced | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/therapeutic use | - |
dc.subject.MESH | Stomatitis/chemically induced | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Alfonsus J.M. van den Eertwegh | - |
dc.contributor.googleauthor | Pierre Karakiewicz | - |
dc.contributor.googleauthor | Sevil Bavbek | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Sergio Bracarda | - |
dc.contributor.googleauthor | Amit Bahl | - |
dc.contributor.googleauthor | Yen-chuan Ou | - |
dc.contributor.googleauthor | Dennis Kim | - |
dc.contributor.googleauthor | Ashok Panneerselvam | - |
dc.contributor.googleauthor | Oezlem Anak | - |
dc.contributor.googleauthor | Viktor Grünwald | - |
dc.identifier.doi | 10.1016/j.urology.2012.09.019 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02775 | - |
dc.identifier.eissn | 1527-9995 | - |
dc.identifier.pmid | 23273080 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0090429512011107 | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Anemia/chemically induced | - |
dc.subject.keyword | Antineoplastic Agents/adverse effects* | - |
dc.subject.keyword | Antineoplastic Agents/therapeutic use | - |
dc.subject.keyword | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.keyword | Carcinoma, Renal Cell/secondary | - |
dc.subject.keyword | Disease Progression | - |
dc.subject.keyword | Dyspnea/chemically induced | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Fatigue/chemically induced | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Hyperglycemia/chemically induced | - |
dc.subject.keyword | Kidney Neoplasms/drug therapy* | - |
dc.subject.keyword | Kidney Neoplasms/pathology | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Pneumonia/chemically induced | - |
dc.subject.keyword | Sirolimus/adverse effects | - |
dc.subject.keyword | Sirolimus/analogs & derivatives* | - |
dc.subject.keyword | Sirolimus/therapeutic use | - |
dc.subject.keyword | Stomatitis/chemically induced | - |
dc.subject.keyword | Time Factors | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 81 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 143 | - |
dc.citation.endPage | 149 | - |
dc.identifier.bibliographicCitation | UROLOGY, Vol.81(1) : 143-149, 2013 | - |
dc.identifier.rimsid | 29073 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.